Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence | Zendy

Dale N. Gerding | Zendy; Ciarán P. Kelly | Zendy; Galia Rahav | Zendy; Christine Lee | Zendy; Erik R. Dubberke | Zendy; Princy Kumar | Zendy; Bruce Yacyshyn | Zendy; Dina Kao | Zendy; Karen Eves | Zendy; Misoo C. Ellison | Zendy; Mary E. Hanson | Zendy; Dalya Güriş | Zendy; Marcus Dörr | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence

Author(s) -

Dale N. Gerding,

Ciarán P. Kelly,

Galia Rahav,

Christine Lee,

Erik R. Dubberke,

Princy Kumar,

Bruce Yacyshyn,

Dina Kao,

Karen Eves,

Misoo C. Ellison,

Mary E. Hanson,

Dalya Güriş,

Marcus Dörr

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy171

Subject(s) - medicine , clostridium difficile , clostridium infections , clostridium , surgery , microbiology and biotechnology , antibiotics , bacteria , biology , genetics

Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin B indicated to prevent C. difficile infection (CDI) recurrence (rCDI) in adults at high risk for rCDI. This post hoc analysis of pooled monocolonal antibodies for C.difficile therapy (MODIFY) I/II data assessed bezlotoxumab efficacy in participants with characteristics associated with increased risk for rCDI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research